表观遗传控制癌症细胞休眠和在激素治疗抵抗中的觉醒。
Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance.
机构信息
Cancer Computational Biology Group, Vall d'Hebron Institute of Onco-logy, Barcelona, Spain.
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
出版信息
Cancer Discov. 2024 May 1;14(5):704-706. doi: 10.1158/2159-8290.CD-24-0282.
Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro. See related article by Rosano et al., p. 866 (9).
罗萨诺、西马利、迪曼等人的研究表明，在雌激素受体阳性（ER+）乳腺癌的内分泌治疗（ET）诱导休眠及其苏醒过程中，会发生与表观遗传相关的变化。针对这些表观遗传变化可以阻止休眠的发生，并减少持久癌细胞的数量，从而增强 ET 在体外的细胞毒性作用。详见罗萨诺等人的相关文章，第 866 页（9）。
Zotero 插件